Abstract:<p>Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.</p>

Progress In Non-Classical Antitumor Platinum Drugs

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Fresh platinum complexes with promising antitumor activity.

Platinum(IV) antitumor complexes and their nano-drug delivery

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

Platinum Drugs: from Pt(II) Compounds, Pt(IV) Prodrugs, to Pt Nanocrystals/nanoclusters.

Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

[Current status of and future perspectives for platinum antitumor drugs]

Recent Advances of Platinum-Based Anticancer Complexes in Combinational Multimodal Therapy

Monofunctional Platinum(II) Anticancer Agents

Platinum-based drugs for cancer therapy and anti-tumor strategies

Clinical Evaluation on Platinum Anticancer Drugs

Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds

Research progress of natural product-conjugated platinum and gold complexes as potential antitumor agents

Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity

Pt(II) and Au(III) complexes containing Schiff-base ligands: A promising source for antitumor treatment

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Advances in Drug Delivery System for Platinum Agents Based Combination Therapy.

Recent Advances in Nanocarriers for Clinical Platinum(ii) Anticancer Drugs